Bufalin inhibits hepatocellular carcinoma progression by blocking EGFR-mediated RAS-RAF-MEK-ERK pathway activation
Our observational data suggest a potential association between Cinobufacini use and favorable trends in OS and PFS among HCC patients. BF exerts its antitumor effects against HCC by interfering with the EGFR-mediated RAS/RAF/MEK/ERK signaling pathway. These findings not only elucidate the molecular mechanisms underlying the antitumor actions of BF but also highlight the potential of Cinobufacini preparations as a valuable therapeutic option for HCC.
Authors
- Lexi Liu
- Weiqi Nian (ORCID: https://orcid.org/0000-0003-0804-8562)
- Ju Huang (ORCID: https://orcid.org/0000-0003-4280-0690)
- Jianyuan Tang (ORCID: https://orcid.org/0000-0003-1096-5917)
- Jia Jiang (ORCID: https://orcid.org/0009-0002-7616-2498)
- Jingwen Liu (ORCID: https://orcid.org/0000-0001-6472-5025)
- Liu Y (ORCID: https://orcid.org/0000-0003-2030-643X)
- Zhilei Wang
Institutions
- First People's Hospital of Chongqing (CN)
- Chengdu University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1186/s13046-025-03531-3
- Citations
- 5
- Primary Topic
- Microbial Natural Products and Biosynthesis
- Type
- article
- Field-Weighted Citation Impact
- 6.97
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Chengdu University of Traditional Chinese Medicine
- Chengdu University
- Natural Science Foundation of Sichuan Province